Precigen (PGEN) Cash from Investing Activities (2012 - 2026)
Precigen (PGEN) reported Cash from Investing Activities of $21.0 million for Q1 2026, up 424.72% year-over-year from $4.0 million in Q1 2025, and down 47.41% quarter-over-quarter from $39.9 million in Q4 2025.
Precigen (PGEN) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Cash from Investing Activities data on file, last reported at $21.0 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $21.0 million, up 424.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.9 million (up 150.55% YoY), and the FY2025 annual result was -$1.5 million, up 92.59% from the prior year.
- Cash from Investing Activities eased to $21.0 million in Q1 2026 per PGEN's latest filing, from $39.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $181.9 million in Q3 2022 and troughed at -$65.4 million in Q4 2024.
- A 5-year average of $13.1 million and a median of $15.0 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities jumped 726.13% in 2022, then slumped 1221.28% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at $11.4 million in 2022, then advanced by 16.39% to $13.3 million in 2023, then tumbled by 591.74% to -$65.4 million in 2024, then jumped by 160.99% to $39.9 million in 2025, then sank by 47.41% to $21.0 million in 2026.
- Business Quant data shows PGEN's Cash from Investing Activities at $21.0 million in Q1 2026, $39.9 million in Q4 2025, and -$63.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn | 20.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.97 Mn |
| Mar 31, 2026 | 20.97 Mn |
| Dec 31, 2025 | 39.87 Mn |
| Dec 31, 2025 | 39.87 Mn |
| Sep 30, 2025 | -63.39 Mn |
| Sep 30, 2025 | -63.39 Mn |
| Jun 30, 2025 | 28.44 Mn |
| Jun 30, 2025 | 28.44 Mn |
| Mar 31, 2025 | -6.46 Mn |
| Mar 31, 2025 | -6.46 Mn |
| Dec 31, 2024 | -65.37 Mn |
| Dec 31, 2024 | -65.37 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Mar 31, 2024 | 24.05 Mn |
| Mar 31, 2024 | 24.05 Mn |
| Dec 31, 2023 | 13.29 Mn |
| Dec 31, 2023 | 13.29 Mn |